Formulated for chronic hepatitis c to target viral replication and support systemic viral clearance.
Mechanism of Action
Sofosbuvir inhibits NS5B RNA polymerase while velpatasvir targets the NS5A protein. This pangenotypic combination prevents the replication and assembly of the Hepatitis C virus across all genotypes.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
12 weeks (treatment course)
Contraindications
Concurrent use of potent CYP inducers, Hypersensitivity to any component
Severe Adverse Events
Severe bradycardia, Hepatitis b reactivation, Anaphylaxis — requires immediate medical attention
Common Side Effects
Headache, Fatigue, Nausea
Uncommon Side Effects
Insomnia, Anemia, Diarrhea
Drug Interactions
Amiodarone, Rifampin, St. John's Wort, Alcohol, Proton Pump Inhibitors
Pregnancy Safety Warnings
FDA Category B: No evidence of fetal risk. Breastfeeding: Excretion in milk is unknown.
Age Restrictions
Safety and efficacy established in pediatric patients three years and older.
Information related to Velpanat is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
